logo
logo

Neuroelectrics Raises $17.5M To Advance Clinical Trials For The Treatment Of Epilepsy And Major Depressive Disorder With A New Platform For Treating Brain Dysfunction

Neuroelectrics Raises $17.5M To Advance Clinical Trials For The Treatment Of Epilepsy And Major Depressive Disorder With A New Platform For Treating Brain Dysfunction

05/04/21, 2:07 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$17.5 million
Neuroelectrics, a pioneer in brain stimulation technologies and therapies, has raised $17.5M in a Series A financing led by Morningside Ventures. The funds will be used to further develop Neuroelectrics’ non-invasive transcranial electrical stimulation (tES) therapeutic platform and to advance clinical trials in refractory focal epilepsy and at-home treatment of refractory depression.

Company Info

Company
Neuroelectrics
Location
cambridge, maryland, united states
Additional Info
Neuroelectrics is developing a therapeutic platform that uses neuromodulation for the treatment of a range of neurological and psychiatric disorders. The platform combines safe and proven neuromodulation capabilities with remote-controlled delivery and personalized treatment protocols to restore and maintain brain health. Based in Cambridge, Massachusetts and Barcelona, Neuroelectrics has an expanding pipeline of computationally driven solutions for neurologic and psychiatric disease. Visit www.neuroelectrics.com.